Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 15/20 | 0.66 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31675939 | 1.00 | SPPL2A (0.66) | SPPL2ACNR1CNR2HPGDNPC1 | |
| SCHEMBL31676115 | 0.96 | SPPL2A (0.64) | SPPL2ACNR1CNR2NPC1MAPT | |
| SCHEMBL31676113 | 0.96 | SPPL2A (0.64) | SPPL2ACNR1CNR2NPC1MAPT | |
| SCHEMBL31676245 | 0.93 | SPPL2A (0.66) | SPPL2ACNR1CNR2 | |
| SCHEMBL31675958 | 0.93 | SPPL2A (0.66) | SPPL2ACNR1CNR2 | |
| SCHEMBL26853473 | 0.91 | SPPL2A (0.79) | SPPL2ACNR1CNR2 | |
| SCHEMBL31676094 | 0.90 | SPPL2A (0.54) | SPPL2A | |
| SCHEMBL31676188 | 0.90 | SPPL2A (0.54) | SPPL2A | |
| SCHEMBL31676323 | 0.90 | SPPL2A (0.54) | SPPL2ANPC1RAB9A | |
| SCHEMBL31676036 | 0.90 | SPPL2A (0.54) | SPPL2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | INCYTE CORPORATION | 2025-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | SPPL2A 1/4885CNR1 4623/4885CNR2 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.